DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the first quarter of 2007. First quarter 2007 revenues were $1.74 million compared to $1.79 million for the first quarter of 2006. In addition, Neoprobe reported a net loss of $1.11 million or $0.02 per share for the quarter compared to a loss of $928,000 or $0.02 per share for the comparable period in 2006. Operating expenses decreased to $1.65 million for the first quarter of 2007 from $1.69 million for the first quarter of 2006. The net loss for the first quarter of 2007 included $382,000 in non-cash charges compared to non-cash charges of $397,000 for the first quarter of 2006. Non-cash charges for both periods consisted primarily of the amortization of warrant and debt-issuance costs related to the financing that was completed in December 2004 in addition to depreciation and amortization of fixed and intangible assets.
